Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-on study of intracerebroventricular sNN0029 in ALS
NL-OMON42272Active, not recruiting
- Sponsor
- Newron Pharmaceuticals
- Start
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of telbermin in amyotrophic lateral sclerosis (ALS), sponsored by Newron Pharmaceuticals. Primary endpoints: Adverse events and tolerability, Clinical safety assessments and 4 more. Started Jan 2015; status: active, not recruiting.
02
Drugs
telbermin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON42272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42272.